Drug Profile
Remimazolam - PAION
Alternative Names: Anerem; ByFavo; ByfavoT; CNS-7056; CNS-7056B; CNS-7056X; ONO-2745; Remimazolam besylate - PAION; RuimaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Acacia Pharma; Hana Pharm; Mundipharma International; PAION; R-Pharm; Yichang Humanwell Pharmaceutical
- Class Benzodiazepines; General anaesthetics; Halogenated hydrocarbons; Hypnosedatives; Imidazoles; Local anaesthetics; Propionates; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Anaesthesia; Sedation
Most Recent Events
- 26 Jan 2023 Committee for Medicinal Products for Human Use adopts a positive opinion in recommending a new strength of remimazolam for Sedation in Europe
- 09 Jun 2022 Acacia Pharma has been acquired by Eagle Pharmaceuticals
- 28 Mar 2022 Eagle Pharmaceuticals plans to acquire Acacia Pharma in between 15th May-30th June 2022